Metformin Plus Low-Dose Glimeperide Significantly Improves Homeostasis Model Assessment for Insulin Resistance (HOMAIR) and β-Cell Function (HOMAβ-cell) Without Hyperinsulinemia in Patients With Type 2 Diabetes Mellitus

Abstract

Metformin plus low-dose glimepiride (plus ADA diet and physical activity) is a more effective treatment for type 2 diabetes than either metformin plus ADA diet and physical activity or ADA diet and physical activity alone. Determination of HOMA(IR) and HOMA(beta-cell) values is an inexpensive, reliable, less invasive, and less labor-intensive method than other tests to estimate insulin resistance and beta-cell function in patients with type 2 diabetes mellitus.